In one paragraphArticle in International journal of molecular sciences, 2026. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.
0numbers the graph read from it
0cells of the map it votes in
0citing papers in PubMed
–field-weighted citation impact
1 · What the graph read from itWhat it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
2 · The registryThe trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
3 · Its place in the literatureWho cites it
0 citing papers in PubMed.
No citing paper in PubMed yet.
4 · The recordCorrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
5 · Who and what moneyAuthors and funding
5 authors.
Alejandro Pinta-CastroFacultad Mexicana de Medicina, Universidad La Salle, México City 14100, Mexico.
Gabriela Michel-UreñaFacultad Mexicana de Medicina, Universidad La Salle, México City 14100, Mexico.
Alejandra Paulina Pérez-GonzálezDivisión de Genómica Computacional, Instituto Nacional de Medicina Genómica, México City 14610, Mexico.ORCID 0000-0001-7352-4444 Guillermo De Anda-JáureguiDivisión de Genómica Computacional, Instituto Nacional de Medicina Genómica, México City 14610, Mexico.
Enrique Hernández-LemusDivisión de Genómica Computacional, Instituto Nacional de Medicina Genómica, México City 14610, Mexico.ORCID 0000-0002-1872-1397 Funding
Alzheimer's Disease Genetics ConsortiumU01AG032984 · NIA · UNIVERSITY OF PENNSYLVANIA · PI SCHELLENBERG, GERARD DAVID · 2009 to 2024
$60.4MSUPPLEMENT TO RUSH ALZHEIMERS DISEASE CENTER COREP30AG010161 · NIA · RUSH UNIVERSITY MEDICAL CENTER · PI BENNETT, DAVID ALAN · 1991 to 2020
$49.1MEPIDEMIOLOGY OF NEURAL RESERVE AND NEUROBIOLOGY IN AGINGR01AG017917 · NIA · RUSH UNIVERSITY MEDICAL CENTER · PI BENNETT, DAVID ALAN · 2001 to 2023
$43.3MRISK FACTORS, PATHOLOGY, AND CLINICAL EXPRESSIONS OF ADR01AG015819 · NIA · RUSH UNIVERSITY MEDICAL CENTER · PI BENNETT, DAVID ALAN · 1998 to 2024
$21.4MMulti-omic network-directed proteoform discovery, dissection and functional validation to prioritize novel AD therapeutic targetsU01AG061356 · NIA · COLUMBIA UNIVERSITY HEALTH SCIENCES · PI BENNETT, DAVID ALAN, DE JAGER, PHILIP L · 2018 to 2022
$13.7MPathway discovery, validation and compound identification for Alzheimer's disease - SupplementU01AG046152 · NIA · COLUMBIA UNIVERSITY HEALTH SCIENCES · PI BENNETT, DAVID ALAN, DE JAGER, PHILIP L · 2013 to 2017
$13.6MDiscovery of Novel Proteomic Targets in Alzheimer's DiseaseU01AG046161 · NIA · EMORY UNIVERSITY · PI BENNETT, DAVID ALAN, GESCHWIND, DANIEL H · 2014 to 2018
$8.4MGenetic Epidemiology of Cognitive Decline in an Aging Population SampleR01AG030146 · NIA · RUSH UNIVERSITY MEDICAL CENTER · PI EVANS, DENIS A · 2007 to 2018
$6.2MExploring the Role of the Brain Epigenome: Cognitive Decline and Life ExperiencesR01AG036042 · NIA · RUSH UNIVERSITY MEDICAL CENTER · PI BENNETT, DAVID ALAN · 2009 to 2013
$4.1MDeconstructing and modeling the single cell architecture of the Alzheimer brainRF1AG057473 · NIA · COLUMBIA UNIVERSITY HEALTH SCIENCES · PI BENNETT, DAVID ALAN, DE JAGER, PHILIP L · 2017 to 2018
$4.0MExploring the Role of the Brain Transcriptome in Cognitive DeclineR01AG036836 · NIA · BRIGHAM AND WOMEN'S HOSPITAL · PI DE JAGER, PHILIP L · 2011 to 2014
$2.9MIdentifying, validating and targeting AD susceptibility networks in monocytesR01AG048015 · NIA · COLUMBIA UNIVERSITY HEALTH SCIENCES · PI DE JAGER, PHILIP L · 2014 to 2018
$1.9MNIA NIH HHS P30 AG010161NIA NIH HHS R01 AG015819NIA NIH HHS R01 AG017917NIA NIH HHS R01 AG030146NIA NIH HHS R01 AG036042NIA NIH HHS R01 AG036836NIA NIH HHS R01 AG048015NIA NIH HHS RC2 AG036547NIA NIH HHS RF1 AG057473NIA NIH HHS U01 AG032984NIA NIH HHS U01 AG046152NIA NIH HHS U01 AG046161NIA NIH HHS U01 AG061356Secretaría de Ciencia Tecnología e Innovación 904078
6 · The paper itselfAbstract
Alzheimer's disease (AD) is a multifactorial neurodegenerative disorder characterized by the simultaneous disruption of interconnected molecular pathways, yet the structural mechanisms underlying this transcriptional disintegration remain poorly characterized. To address this, we constructed condition-specific gene co-expression networks from DLPFC bulk RNA-seq data, using a mutual-information (MI) framework with infomap community partitioning. Functional enrichment of network communities via Ingenuity Pathway Analysis (IPA) identified GABAergic signaling, SNARE complex assembly, Synaptogenesis, and neurexin and neuroligin interactions as significantly overrepresented pathways. Integration of node degree with condition-specific average expression revealed coordinated topological centralization of key synaptic genes-including NRXN2, LRRTM1, DLGAP3, and SHANK1-alongside a widespread transcriptional downregulation in GABAergic and Synaptogenesis modules. A shortest-path analysis revealed a consistent expansion of intra-pathway distances across all evaluated canonical pathways in AD, a pattern statistically consistent with reduced local co-expression cohesion. These findings reframe Late-Onset Alzheimer's Disease (LOAD) as an active structural-rewiring process, in which the observed topological centralization pattern seems to be consistent with a consolidation of co-expression around synaptic components, though we cannot exclude that shifts in cellular composition contribute to this signal in bulk RNA-seq data.
Indexed as
Alzheimer DiseaseGene Regulatory NetworksSignal TransductionHumansNeurexinsNeuroliginsSNARE ProteinsNeurexinsNeuroliginsSNARE ProteinsAlzheimer’s diseasecanonical pathwaysco-expression networksGABAergicglutamatergicneurexins and neuroliginsSNAREsynaptogenesis
Identifiers
PMID42278365
PMCPMC13256824
What OpenQuestion holds
Textmetadata
LicenceCC BY
Read underepoch 390